

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

ACTINOGEN LIMITED

ABN

14 086 778 476

Quarter ended ("current quarter")

31 December 2014

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) staff costs	(24)	(33)
(b) advertising and marketing	-	-
(c) research and development	(517)	(570)
(d) leased assets	-	-
(e) other working capital	(148)	(257)
(f) corporate reconstruction costs	-	-
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	11	18
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other (R&D tax rebate)	104	104
<b>Net operating cash flows</b>	<b>(574)</b>	<b>(738)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	(574)	(738)
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses-stamp duty & VAT paid on acquisition of Corticrine Limited <sup>1</sup>	(491)	(491)
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
	<b>1. Note: VAT refund of approximately AUD \$450,000 (GBP 238,000) due in March quarter.</b>		
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	21	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	(30)	(30)
	<b>Net investing cash flows</b>	<b>(500)</b>	<b>(521)</b>
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>(1,074)</b>	<b>(1,259)</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares, options (net of capital raising costs)	1,153	2,148
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other – share application monies re Tranche 2 Placement	-	35
	<b>Net financing cash flows</b>	<b>1,153</b>	<b>2,183</b>
	<b>Net increase (decrease) in cash held</b>	<b>79</b>	<b>924</b>
1.21	Cash at beginning of quarter/year to date	1,973	1,128
1.22	Exchange rate adjustments to item 1.20	-	-
<b>1.23</b>	<b>Cash at end of quarter</b>	<b>2,052</b>	<b>2,052</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	49
1.25	Aggregate amount of loans from the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions 1.24 – payments relate to Directors Fees paid during the quarter.	

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

On 1 December 2014, Actinogen Limited issued 125,000,000 fully paid shares at a deemed issue price of 4.4 cents per share to acquire 100% of the issued capital of Corticrine Limited.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

## Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	71	22
4.2 Deposits at call	1,981	1,951
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.23)</b>	<b>2,052</b>	<b>1,973</b>


## Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Corticrine Limited	Nil
5.2 Place of incorporation or registration	Scotland	
5.3 Consideration for acquisition or disposal	125,000,000 fully paid ordinary shares at a deemed issue price of 4.4 cents per share (non-cash).	
5.4 Total net assets	(\$49,320)	
5.5 Nature of business	Development of novel treatments for Alzheimer's disease other age related neurodegenerative disorders.	

## Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Company Secretary

Date: 28 January 2015

Print name: Peter Webse

+ See chapter 19 for defined terms.

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.